David Bourget (Western Ontario)
David Chalmers (ANU, NYU)
Rafael De Clercq
Jack Alan Reynolds
Learn more about PhilPapers
Developing World Bioethics 12 (3):121-134 (2012)
Most of the world's health problems afflict poor countries and their poorest inhabitants. There are many reasons why so many people die of poverty-related causes. One reason is that the poor cannot access many of the existing drugs and technologies they need. Another, is that little of the research and development (R&D) done on new drugs and technologies benefits the poor. There are several proposals on the table that might incentivize pharmaceutical companies to extend access to essential drugs and technologies to the global poor.1 Still, the problem remains – the poor are suffering and dying from lack of access to essential medicines. So, it is worth considering a new alternative. This paper suggests rating pharmaceutical and biotechnology companies based on how some of their policies impact poor people's health. It argues that it might be possible to leverage a rating system to encourage companies to extend access to essential drugs and technologies to the poor
|Keywords||poverty developing countries developing world bioethics health pharmaceutical essential medicines neglected disease|
|Categories||categorize this paper)|
Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
|Through your library|
References found in this work BETA
No references found.
Citations of this work BETA
No citations found.
Similar books and articles
Klaus M. Leisinger (2012). Poverty, Disease, and Medicines in Low- and Middle-Income Countries. Business and Professional Ethics Journal 31 (1):135-185.
Anand Grover, Brian Citro, Mihir Mankad & Fiona Lander (2012). Pharmaceutical Companies and Global Lack of Access to Medicines: Strengthening Accountability Under the Right to Health. Journal of Law, Medicine and Ethics 40 (2):234-250.
Meri Koivusalo (2010). Common Health Policy Interests and the Shaping of Global Pharmaceutical Policies. Ethics and International Affairs 24 (4):395-414.
Devi Sridhar (2008). Improving Access to Essential Medicines: How Health Concerns Can Be Prioritised in the Global Governance System. Public Health Ethics 1 (2):83-88.
Michael Ravvin (2008). Incentivizing Access and Innovation for Essential Medicines: A Survey of the Problem and Proposed Solutions. Public Health Ethics 1 (2):110-123.
Joo-Young Lee & Paul Hunt (2012). Human Rights Responsibilities of Pharmaceutical Companies in Relation to Access to Medicines. Journal of Law, Medicine and Ethics 40 (2):220-233.
Onyeka K. Osuji & Okechukwu Timothy Umahi (2012). Pharmaceutical Companies and Access to Medicines – Social Integration and Ethical CSR Resolution of a Global Public Choice Problem. Journal of Global Ethics 8 (2-3):139-167.
N. Craig Smith & Anne Duncan (2005). GlaxoSmithKline and Developing Country Access to Essential Medicines (A). Journal of Business Ethics Education 2 (1):97-121.
Javier Hidalgo (2012). Why Restrictions on the Immigration of Health Workers Are Unjust. Developing World Bioethics 12 (3):117-126.
Frank R. Lichtenberg (2005). Pharmaceutical Innovation and the Burden of Disease in Developing and Developed Countries. Journal of Medicine and Philosophy 30 (6):663 – 690.
Klaus M. Leisinger (2009). Corporate Responsibilities for Access to Medicines. Journal of Business Ethics 85 (1):3 - 23.
Klaus M. Leisinger (2005). The Corporate Social Responsibility of The Pharmaceutical Industry. Business Ethics Quarterly 15 (4):577-594.
David Barnard (2002). In the High Court of South Africa, Case No. 4138/98: The Global Politics of Access to Low-Cost AIDS Drugs in Poor Countries. [REVIEW] Kennedy Institute of Ethics Journal 12 (2):159-174.
Thomas Alured Faunce & Hitoshi Nasu (2008). Three Proposals for Rewarding Novel Health Technologies Benefiting People Living in Poverty. A Comparative Analysis of Prize Funds, Health Impact Funds and a Cost-Effectiveness/Competitive Tender Treaty. Public Health Ethics 1 (2):146-153.
Jorn Sonderholm (2009). In Defence of Priority Review Vouchers. Bioethics 23 (7):413-420.
Added to index2012-02-08
Total downloads10 ( #154,106 of 1,101,843 )
Recent downloads (6 months)3 ( #128,836 of 1,101,843 )
How can I increase my downloads?